Skye Bioscience, Inc. Common Stock (SKYE) - Total Assets
Based on the latest financial reports, Skye Bioscience, Inc. Common Stock (SKYE) holds total assets worth $28.31 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Skye Bioscience, Inc. Common Stock (SKYE) net assets for net asset value and shareholders' equity analysis.
Skye Bioscience, Inc. Common Stock - Total Assets Trend (2012–2025)
This chart illustrates how Skye Bioscience, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
Skye Bioscience, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Skye Bioscience, Inc. Common Stock's total assets of $28.31 Million consist of 95.7% current assets and 4.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.8% |
| Accounts Receivable | $10.47K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Skye Bioscience, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SKYE market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Skye Bioscience, Inc. Common Stock's current assets represent 95.7% of total assets in 2025, an increase from 89.4% in 2012.
- Cash Position: Cash and equivalents constituted 20.8% of total assets in 2025, down from 61.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Skye Bioscience, Inc. Common Stock Competitors by Total Assets
Key competitors of Skye Bioscience, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Skye Bioscience, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.30 | 16.32 | 3.89 |
| Quick Ratio | 3.30 | 16.32 | 3.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $18.89 Million | $66.49 Million | $4.00 Million |
Skye Bioscience, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Skye Bioscience, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.16 |
| Latest Market Cap to Assets Ratio | 0.83 |
| Asset Growth Rate (YoY) | -61.1% |
| Total Assets | $28.31 Million |
| Market Capitalization | $23.61 Million USD |
Valuation Analysis
Near Book Valuation: The market values Skye Bioscience, Inc. Common Stock's assets close to their book value (0.83x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Skye Bioscience, Inc. Common Stock's assets decreased by 61.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Skye Bioscience, Inc. Common Stock (2012–2025)
The table below shows the annual total assets of Skye Bioscience, Inc. Common Stock from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $28.31 Million | -61.09% |
| 2024-12-31 | $72.76 Million | +509.39% |
| 2023-12-31 | $11.94 Million | +31.05% |
| 2022-12-31 | $9.11 Million | -7.55% |
| 2021-12-31 | $9.86 Million | +268.87% |
| 2020-12-31 | $2.67 Million | +33.80% |
| 2019-12-31 | $2.00 Million | +2.02% |
| 2018-12-31 | $1.96 Million | +251.23% |
| 2017-12-31 | $557.22K | +72.32% |
| 2016-12-31 | $323.36K | -90.79% |
| 2015-12-31 | $3.51 Million | +907.92% |
| 2014-12-31 | $348.35K | +139.09% |
| 2013-12-31 | $145.69K | +239.74% |
| 2012-12-31 | $42.88K | -- |
About Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company wa… Read more